Overview

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Status:
Not yet recruiting

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Jaeb Center for Health Research

Collaborators:

Alimera Sciences
Genentech, Inc.
National Eye Institute (NEI)
National Institutes of Health (NIH)

Treatments:

Fluocinolone Acetonide